Cargando…

Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer

Despite improvements in outcome, 15-25% of newly diagnosed multiple myeloma (MM) patients have treatment resistant high-risk (HR) disease with a poor survival. The lack of a genetic basis for HR has focused attention on the role played by epigenetic changes. Aberrant expression and somatic mutation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghamlouch, Hussein, Boyle, Eileen M., Blaney, Patrick, Wang, Yubao, Choi, Jinyoung, Williams, Louis, Bauer, Michael, Auclair, Daniel, Bruno, Benedetto, Walker, Brian A., Davies, Faith E., Morgan, Gareth J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638425/ https://www.ncbi.nlm.nih.gov/pubmed/34857028 http://dx.doi.org/10.1186/s13046-021-02185-1

Ejemplares similares

The evolving role and utility of off-label drug use in multiple myeloma
por: Stoeckle, James H, et al.
Publicado: (2021)

Structural variants shape the genomic landscape and clinical outcome of multiple myeloma
por: Ashby, Cody, et al.
Publicado: (2022)

Identifying 1q amplification and PHF19 expressing high-risk cells associated with relapsed/refractory multiple myeloma
por: Johnson, Travis S., et al.
Publicado: (2023)

Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease
por: Mason, Mike J., et al.
Publicado: (2020)

Differential RNA splicing as a potentially important driver mechanism in multiple myeloma
por: Bauer, Michael A., et al.
Publicado: (2020)

Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients
por: Caro, Jessica, et al.
Publicado: (2022)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
por: Boyle, Eileen M., et al.
Publicado: (2021)

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma
por: Qiang, Ya-Wei, et al.
Publicado: (2018)

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
por: Davies, Faith E., et al.
Publicado: (2022)

The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma
por: Mikulasova, Aneta, et al.
Publicado: (2017)

The genomic features associated with high-risk multiple myeloma
por: Walker, Brian A., et al.
Publicado: (2018)

Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma
por: Mikulasova, Aneta, et al.
Publicado: (2020)

The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma
por: Choudhury, Samrat Roy, et al.
Publicado: (2020)

Mechanistic insights into chromatin targeting by leukemic NUP98-PHF23 fusion
por: Zhang, Yi, et al.
Publicado: (2020)

Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
por: Pawlyn, Charlotte, et al.
Publicado: (2018)

Residue-based propensity of aggregation in the Tau amyloidogenic hexapeptides AcPHF6* and AcPHF6
por: Dangi, Abha, et al.
Publicado: (2020)

Characterization of a Novel Mouse Model of Multiple Myeloma and Its Use in Preclinical Therapeutic Assessment
por: Fryer, Rosemary A., et al.
Publicado: (2013)

The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
por: Rasche, Leo, et al.
Publicado: (2022)

Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
por: Maclachlan, Kylee H., et al.
Publicado: (2021)

PHF6 Mutations in Hematologic Malignancies
por: Kurzer, Jason H., et al.
Publicado: (2021)

A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma
por: Boyle, Eileen M, et al.
Publicado: (2015)

Correction: Residue-based propensity of aggregation in the Tau amyloidogenic hexapeptides AcPHF6* and AcPHF6
por: Dangi, Abha, et al.
Publicado: (2022)

The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway
por: Smith, Emma M., et al.
Publicado: (2013)

The Importance of an In-depth Study of Immunoglobulin Gene Rearrangements When Ascertaining the Clonal Relationship between Concomitant Chronic Lymphocytic Leukemia and Multiple Myeloma
por: Trudel, Stéphanie, et al.
Publicado: (2016)

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma
por: Walker, Brian A, et al.
Publicado: (2015)

The sequential phosphorylation of PHF10 subunit of the PBAF chromatin-remodeling complex determines different properties of the PHF10 isoforms
por: Sheynov, Andrey A., et al.
Publicado: (2020)

Molecular profiling in myeloma
por: Pawlyn, Charlotte, et al.
Publicado: (2018)

Mechanistic insights into remodeled Tau-derived PHF6 peptide fibrils by Naphthoquinone-Tryptophan hybrids
por: KrishnaKumar, V. Guru, et al.
Publicado: (2018)

Computational Insights Into the Inhibition Mechanism of Proanthocyanidin B2 on Tau Hexapeptide (PHF6) Oligomer
por: Li, Qin, et al.
Publicado: (2021)

Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53
por: Ashby, Cody, et al.
Publicado: (2019)

Search for rare protein altering variants influencing susceptibility to multiple myeloma
por: Scales, Matthew, et al.
Publicado: (2017)

Inhibition of spumavirus gene expression by PHF11
por: Kane, Melissa, et al.
Publicado: (2020)

PHF24 is expressed in the inhibitory interneurons in rats
por: Numakura, Yuki, et al.
Publicado: (2020)

A proof-of-concept study for the pathogenetic role of enhancer hypomethylation of MYBPHL in multiple myeloma
por: Wong, Kwan Yeung, et al.
Publicado: (2021)

Expression patterns of Phf5a/PHF5A and Gja1/GJA1 in rat and human endometrial cancer
por: Falck, Eva, et al.
Publicado: (2013)

Structural basis for histone variant H3tK27me3 recognition by PHF1 and PHF19
por: Dong, Cheng, et al.
Publicado: (2020)

Kinase domain activation through gene rearrangement in multiple myeloma
por: Morgan, Gareth J, et al.
Publicado: (2018)

Methyl-lysine readers PHF20 and PHF20L1 define two distinct gene expression–regulating NSL complexes
por: Van, Hieu T., et al.
Publicado: (2022)

Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
por: Bird, Sarah, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0o9hr2941nsbc2s2a3vobuoh5e